Tidmarsh, who has founded and served as CEO of several biotech companies, will lead a crucial FDA division that reviews the majority of new drug applications.
Related Posts
‘Now is the time for restraint:’ World leaders react to Israel’s strikes on Iran
World leaders called for restraint after Israel launched a series of airstrikes on Iran as concerns about the stability of the region mounted.
Gold plunges 3% as Trump Treasury pick and potential Israel-Hezbollah truce fuel risk-on mood
A potential Israel-Hezbollah ceasefire agreement and Bessent’s appointment were the key contributors to the bullion selloff, experts said.
How Trump’s tariffs rollout turned into stock market mayhem
What’s happened is something worse than the worst-case scenario.